



IN VITRO DIAGNOSTIC KIT FOR COLORECTAL CANCER AGGRESSIVENESS

#KEYWORDS

Cancer Initiating Cells
In vitro Diagnostic
Colorectal cancer
Aggressiveness
Immunohistochemistry

CONTEXT

Colorectal cancer is a major public health problem in industrialised countries due to its frequency and severity. Colorectal cancer has a high incidence in France, with 48'000 new cases per year. Even if the detection is performed at always earlier stages, current diagnostic methodology may result into staging errors.

Physicians need new diagnostic tools to discriminate patients at higher risk of relapse, requiring personalized monitoring and therapy.

TECHNOLOGY

Immunohistochemistry test automatized and based on innovative biomarkers for colorectal cancer stem cells. Those tumour initiating cells are involved in the colorectal cancer recurrence process. The early detection of these cells will provide to the clinicians a predictive factor of disease evolution.

This innovation brings new perspectives in colorectal cancer **aggressiveness diagnostic**. Complementary available information for medical teams could help decrease the **decrease risk of relapse or control the gravity of the disease by adaptation of treatments and/or monitoring protocols with a more personalised diagnostic** especially for patients with early TNM stages of colorectal cancer (I and II).

ADVANTAGES / BENEFITS

- Adds previously unknown accuracy in the diagnostic of aggressiveness for colorectal cancer
- New stratification of high risk colorectal cancer patients (positive for cancer initiating cells) especially for early TNM stages (I and II) allows to personalize treatments and monitoring protocols
- Easily applicable with standard anatomo-pathological procedures and complementary to already existing diagnostic process

INTELLECTUAL PROPERTY

- Priority filing (2 pending patents) 2015

PARTNERSHIP

Available for co-development and/or licensing out.

RESEARCH TEAM

Limoges University, FRANCE
EA 3842 Homéostasie Cellulaire
et Pathologies,
Pr Marie-Odile JAUBERTEAU

SATT GRAND CENTRE

is a French tech transfer company having exclusive rights to license out technologies coming out of universities and public research organizations in France.

CONTACT

Magali GRANGER
Business Developer

Tél. +33(0)6 34 22 36 89
Mail : magali.granger@sattgc.com

8, rue Pablo PICASSO
63000 CLERMONT-FERRAND
FRANCE

www.sattgc.com